Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer (A55624) - R8 - Effective March 16, 2022

This Billing and Coding Article has been revised and published for notice under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV).

Effective Date: March 16, 2022

Summary of Article Changes:

Under Article Text added verbiage and hyperlinks for “Refer to Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors for CPT/HCPCS codes and ICD-10 codes relevant for solid tumors. Refer to Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Test for CPT/HCPCS codes and ICD-10 codes relevant for myeloid malignancies”.

Under CPT/HCPCS Codes Group 1: Paragraph deleted the verbiage.

Under CPT/HCPCS Codes Group 1: Codes deleted all CPT/HCPCS codes listed.

Under CPT/HCPCS Group 2: Paragraph deleted the verbiage.

Under CPT/HCPCS Codes Group 2: Codes deleted all CPT/HCPCS codes listed.

Under ICD-10 Codes that Support Medical Necessity Group 1: Paragraph deleted the verbiage. Under ICD-10 Codes that Support Medical Necessity Group 1: Codes deleted all ICD-10 codes listed. Under ICD-10 Codes that Support Medical Necessity Group 2: Paragraph deleted the verbiage. Under ICD-10 Codes that Support Medical Necessity Group 2: Codes deleted all ICD-10 codes listed

Visit the Molecular Diagnostic Services (MolDX) webpage to access the locally hosted MolDX Medicare Coverage Article from the “Covered Tests” or the “Excluded Tests” webpage.

To view the complete listing of locally hosted coverage articles and/or access the Active, Future, or Retired articles available in the CMS MCD, visit the Medicare Coverage Articles webpage.

            Last Updated Wed, 30 Mar 2022 19:28:22 +0000